Caladrius Biosciences Inc
LSE:0HS8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Caladrius Biosciences Inc
LSE:0HS8
|
US |
|
Shri Bajrang Alliance Ltd
BSE:526981
|
IN |
|
S
|
S2Medical AB (publ)
STO:S2M
|
SE |
|
NuGene International Inc
OTC:NUGN
|
US |
|
Lisi SA
OTC:LSIIF
|
FR |
|
Nippon Densetsu Kogyo Co Ltd
TSE:1950
|
JP |
|
Offcn Education Technology Co Ltd
SZSE:002607
|
CN |
|
Trip.com Group Ltd
HKEX:9961
|
CN |
|
N
|
Nusasiri PCL
SET:NUSA
|
TH |
|
Baticim Bati Anadolu Cimento Sanayii AS
IST:BTCIM.E
|
TR |
|
B
|
Bantas Bandirma Ambalaj Sanayi ve Ticaret AS
IST:BNTAS.E
|
TR |
|
C
|
China Merchants Bank Co Ltd
HKEX:3968
|
CN |
Wall Street
Price Targets
0HS8 Price Targets Summary
Caladrius Biosciences Inc
According to Wall Street analysts, the average 1-year price target for 0HS8 is 11.56 USD with a low forecast of 4.04 USD and a high forecast of 15.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is 0HS8's stock price target?
Price Target
11.56
USD
According to Wall Street analysts, the average 1-year price target for 0HS8 is 11.56 USD with a low forecast of 4.04 USD and a high forecast of 15.75 USD.
What is Caladrius Biosciences Inc's Revenue forecast?
Projected CAGR
251%
For the last 14 years the compound annual growth rate for Caladrius Biosciences Inc's revenue is -25%. The projected CAGR for the next 3 years is 251%.
